Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;30(3):365-369.
doi: 10.1097/MOU.0000000000000739.

Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage

Christian Daniel Fankhauser  1 , Jeremy Yuen-Chun Teoh  2 , Hugh Mostafid  3
Affiliations
Free article
Review

Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage

Christian Daniel Fankhauser et al. Curr Opin Urol. 2020 May.
Free article

Abstract

Purpose of review: Given the worldwide shortage of Bacillus Calmette-Guérin (BCG), we review the efficacy of alternative BCG application schedules, doses or strains and intravesical chemotherapy in patients with nonmuscle-invasive bladder cancer (NMIBC).

Recent findings: Modifying BCG schedules by reducing the dose is preferable to reducing the frequency of BCG that increases recurrence rates and should be avoided if possible. Changing the BCG substrain represents a reasonable option, as current evidence does not suggest different oncological outcomes with specific BCG substrains. Mitomycin C (MMC) alone is inferior to BCG with maintenance, but promising results have been demonstrated when used with chemohyperthermia and electromotive drug administration. Several other intravesical chemotherapies including Gemcitabine and Epirubicin should be used when both BCG and MMC are in short supply.

Summary: In case of BCG shortage, much will depend on the severity and length of the BCG shortage, but our review supports several solutions: First, we recommend contacting the local pharmacist or BCG supplier to consider alternative BCG strains or sterile splitting of BCG doses. In the complete absence of BCG, consideration should be given to MMC with chemohyperthermia or electromotive drug administration where available or other intravesical chemotherapy. High-risk patients should be considered for cystectomy.

PubMed Disclaimer

References

    1. Ferlay JSH, Bray F, Forman D, et al. GLOBOCAN 2012Cancer incidence and mortality worldwide [Internet]. 2012; Lyon, France: International Agency for Research on Cancer, http://globocan.iarc.frhttp://globocan.iarc.fr [Accessed 9 August 2017].
    1. Babjuk M, Burger M, Comperat EM, et al. European Association of Urology Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ): 2019 update. Eur Urol 2019; 76:639–657.
    1. Chang Sam S, Boorjian Stephen A, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016; 196:1021–1029.
    1. Davies BJ, Hwang TJ, Kesselheim AS. Ensuring access to injectable generic drugs: the case of intravesical BCG for bladder cancer. N Engl J Med 2017; 376:1401–1403.
    1. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; 63:462–472.

MeSH terms